In a regulatory filing, Horizon Therapeutics disclosed that its CFO Aaron Cox sold 36K shares of common stock on January 13th in a total transaction size of $4.09M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Horizon Therapeutics:1st patient enrolled in Phase 2 daxdilimab trial for DLE
- Horizon Therapeutics announces ANVISA approval for Uplizna
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Viridian Therapeutics initiated with a Buy at Needham
- Horizon Pharma call volume above normal and directionally bullish